Repligen Corp director Hunt Anthony sells $4.08 million in stock

Published 19/03/2025, 21:24
Repligen Corp director Hunt Anthony sells $4.08 million in stock

WALTHAM, MA— Repligen Corp (NASDAQ:RGEN), a biotech company currently valued at $8.2 billion, saw Director Hunt Anthony recently execute significant stock sales, according to a recent SEC filing. InvestingPro analysis shows the company maintains a FAIR financial health score despite currently trading at high valuation multiples. On March 17, Anthony sold a total of 26,756 shares of Repligen common stock, valued at approximately $4.08 million. The sales were conducted under a pre-arranged 10(b)5-1 trading plan, with transaction prices ranging from $148.05 to $153.70 per share. The stock currently trades near $145, with analysts setting price targets between $155 and $225.

In addition to the sales, Anthony also exercised stock options to acquire 26,756 shares of common stock at prices between $33.87 and $59.52, totaling approximately $1.46 million. Following these transactions, Anthony’s direct ownership of Repligen shares stands at 136,301 shares.

These transactions were part of a broader strategy, as indicated by the trading plan adopted in December 2024, and reflect the director’s ongoing management of his equity holdings in the company.

In other recent news, Repligen Corporation reported its fourth-quarter 2024 financial results, showing a slight revenue increase to $167.5 million, up 1% from the previous year. The company’s adjusted earnings per share (EPS) were $0.44, a decrease from $0.48 in the fourth quarter of 2023. Repligen also provided guidance for 2025, projecting revenue growth of 10%-14% and an adjusted EPS between $1.67 and $1.76. In terms of strategic moves, Repligen announced the acquisition of a bioprocessing desktop portfolio for $70 million, which is expected to contribute $12 million in sales by 2025. This acquisition aligns with their growth plans and enhances their existing technology portfolio.

Analysts have expressed varied opinions on Repligen’s stock. Evercore ISI initiated coverage with an In Line rating and a $155 price target, noting the company’s potential for market recovery. Leerink Partners maintained an Outperform rating with a $200 target, highlighting the strategic importance of the recent acquisition. Meanwhile, H.C. Wainwright reiterated a Buy rating and set a $180 price target, citing confidence in the company’s financial outlook and recent innovations. Canaccord Genuity raised its price target to $170 while maintaining a Hold rating, reflecting a positive outlook on margin expansion and market recovery potential. These developments indicate a mix of cautious optimism and strategic positioning for Repligen amidst evolving market conditions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.